Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription by Daniel Abankwa et al.
Abankwa et al. BMC Biochemistry 2013, 14:10
http://www.biomedcentral.com/1471-2091/14/10RESEARCH ARTICLE Open AccessSki-interacting protein (SKIP) interacts with
androgen receptor in the nucleus and modulates
androgen-dependent transcription
Daniel Abankwa1,6, Susan M Millard1,2, Nick Martel1,2, Catherine S Choong3, Miao Yang4, Lisa M Butler4,
Grant Buchanan4,7, Wayne D Tilley4, Nobuhide Ueki5, Michael J Hayman5 and Gary M Leong1,2*Abstract
Background: The androgen receptor (AR) is a member of the nuclear receptor (NR) superfamily of ligand-inducible
DNA transcription factors, and is the major mediator of male sexual development, prostate growth and the
pathogenesis of prostate cancer. Cell and gene specific regulation by the AR is determined by availability of and
interaction with sets of key accessory cofactors. Ski-interacting protein (SKIP; SNW1, NCOA62) is a cofactor shown to
interact with several NRs and a diverse range of other transcription factors. Interestingly, SKIP as part of the
spliceosome is thought to link mRNA splicing with transcription. SKIP has not been previously shown to interact
with the AR.
Results: The aim of this study was to investigate whether SKIP interacts with the AR and modulates AR-dependent
transcription. Here, we show by co-immunoprecipitation experiments that SKIP is in a complex with the AR.
Moreover, SKIP increased 5α-dihydrotestosterone (DHT) induced N-terminal/C-terminal AR interaction from 12-fold
to almost 300-fold in a two-hybrid assay, and enhanced AR ligand-independent AF-1 transactivation. SKIP
augmented ligand- and AR-dependent transactivation in PC3 prostate cancer cells. Live-cell imaging revealed a fast
(half-time=129 s) translocation of AR from the cytoplasm to the nucleus upon DHT-stimulation. Förster resonance
energy transfer (FRET) experiments suggest a direct AR-SKIP interaction in the nucleus upon translocation.
Conclusions: Our results suggest that SKIP interacts with AR in the nucleus and enhances AR-dependent
transactivation and N/C-interaction supporting a role for SKIP as an AR co-factor.Background
SNW/SKIP proteins, which include human Ski-interacting
protein (SKIP; SNW1, NCOA62) and its yeast homologue
the essential splicing factor Prp45 (Pre-mRNA Processing
45) [1], are phylogenetically highly conserved [2], and
important during early development [3,4]. SKIP was iden-
tified by its interaction with the proto-oncogenes, v-Ski
and c-Ski [5]. In addition to pre-mRNA splicing in the
spliceosome [6], SKIP appears to have multiple other func-
tions in transcription [2]. It acts as a transcriptional co-
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reproduction in any medium, provided the orsuch as of CREB binding protein (CBP)/ p300, the nuclear
co-repressor (N-CoR) and silencing mediator for retinoic
acid and thyroid hormone receptors (SMRT) [7]. It also
interacts with a large range of DNA binding proteins, in-
cluding Smad2 and 3 proteins of the TGF-β pathway [8],
and proteins involved in MyoD and Notch signalling [2]
and may be involved in Wnt signalling [9]. A recent study
suggests SKIP regulates the cell cycle arrest factor p21
(Cip1) and subsequent effects on p53-dependent DNA cell
damage [10]. This appeared to involve recruitment of
SKIP to the p21 promoter where SKIP plays a critical role
for splicing and p21 gene expression, suggesting a role of
SKIP in cancer cell apoptosis.
The fundamental effects of SKIP in transcriptional
regulation are supported by its co-regulatory effect on
nuclear hormone receptors, including estrogen receptor
[11], the Vitamin D receptor (VDR) and Retinoid Xal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lates in association with SIRT1 [16]. More recently SKIP
was shown to associate with P-TEFb, c-myc and Menin
to act on the HIV-1 promoter [17,18].
The androgen receptor (AR) is a member of the nuclear
hormone receptor superfamily that regulates male sexual
development, and is a major player in the pathogenesis and
progression of prostate cancer [19-22]. Upon binding to its
natural ligands testosterone and 5α-dihydrotestosterone
(DHT), the AR becomes phosphorylated and translocates
into the nucleus, where it binds as a homodimer to
canonical nuclear receptor inverted repeat DNA response
elements to activate target gene transcription [23]. A
comprehensive ChIP-on-chip analysis of AR-responsive
elements (ARE) on chromosomes 21 and 22 however sug-
gests that the majority of the 90 identified binding sites are
non-canonical, with isolated half-sites, head-to-head, head-
to-tail and direct repeat AREs [24].
The AR contains distinct structural domains also found
in other nuclear receptor superfamily members. The a-
mino (N)-terminal transactivation domain, which is also
termed ligand-independent activation-function-1 domain
(AF-1), is followed by a DNA-binding domain (DBD) that
is linked via a hinge region to a carboxy (C)-terminal
ligand-binding domain (LBD), which contains the activa-
tion function-2 domain (AF-2) [25,26]. Ligand binding in-
duces interaction between the N-terminal and C-terminal
domains of AR [27,28]. This interdomain rearrangement
slows ligand dissociation and AR degradation [29]. More-
over, mutations in the AR AF-2 domain, which are as-
sociated with partial or complete androgen insensitivity
syndrome, also abrogate N/C-interaction in vitro, sugges-
ting that N/C-interaction is functionally important in vivo
[27]. The AR intrinsic N-terminal FXXLF (residues
23–27) and WXXLF (residues 433–437) motifs form
amphipathic α-helices that stabilise the N/C-interaction,
by binding to a hydrophobic pocket at the C-terminus
[30]. Importantly, the intrinsic (F/W)XXLF motifs com-
pete with the similar, extrinsic LXXLL-motif from p160-
family type I co-regulators for the hydrophobic pocket
on the AR C-terminus [31]. Examples for type 1 co-
regulators are steroid receptor co-activators (SRC1 and
SRC3), transcriptional intermediary factor 2 (TIF2) and
amplified in breast cancer-1 (AIB1) [25,32].
While AF-1 mediates hormone-independent constitu-
tive transactivation when artificially isolated, the AF-2 is
inactive in the absence of hormone, but required for
strong, ligand-dependent activity in androgen-dependent
prostate cancer cells [33-36]. This may be due to the fact
that even in the absence of ligand the extended AF-1
fragment (including the DBD) assumes a similar reticu-
lar or speckled distribution to nuclear foci, as the full-
length receptor with its co-regulators, while the isolated
AF-2 is distributed homogenously in the nucleoplasm,even if ligand is added [37]. This speckle-pattern distri-
bution is typical for markers of various nuclear compart-
ments, such as speckles, nucleoli and cajal bodies
[38,39]. Nuclear speckles are sites of pre-mRNA splicing
and SKIP was found among other splicing proteins
enriched in nuclear speckles [40].
In this study, we demonstrate that SKIP interacts with
the AR. We show that SKIP acts in multiple ways, by
augmenting AR AF-1-dependent activity as a classical type
I co-activator, while it also enhanced AR N/C-interaction
and AR-dependent transcription in prostate cancer cells.
Results
Mammalian one-hybrid data show that SKIP augments
ligand-independent AR transcription
SKIP modulates the transcriptional activity of a variety of
nuclear hormone receptors. We therefore tested, whether
SKIP can also act as a co-regulator of androgen receptor
(AR), which is critically involved in prostate cancer [19,22].
To address, whether SKIP influences AR-mediated trans-
activation, we used a mammalian one-hybrid assay, which
assesses the transcriptional co-activating property of a can-
didate protein (e.g. SKIP) on a potential interaction partner
(e.g. AR) fused to the GAL4 DNA binding domain. The
presence of the co-activator increases binding of the fusion
protein to GAL4-binding sites on the reporter plasmid,
which then drives luciferase transcription [41]. We ex-
pressed in HEK293 cells a fragment comprising the N-
terminal ligand-independent activation-function-1 (AF-1)
domain of AR (residues 1–555) fused to the GAL4 DNA
binding domain (AR1-555) with and without SKIP. In the
absence of the AR1-555 fusion protein, overexpression of
SKIP did not induce reporter gene expression compared to
control cells co-transfected with empty vectors (Figure 1).
Consistent with the ligand-independent transcriptional
activity of the AR AF-1 domain [42], transfection of the
AR1-555 fusion protein induced a 10-fold increase in
basal, ligand-independent luciferase activity compared to
control levels. This AR-AF-1 transcriptional activity was
increased ~5-fold by overexpression of SKIP (Figure 1).
These data suggest a co-stimulatory activity of SKIP
by a functional interaction with the N-terminal ligand-
independent activation-function-1 (AF-1) domain of AR.
SKIP facilitates interaction of AR N- and C-termini
AR transcriptional activity is modulated by ligand-mediated
interdomain interaction of its N- and C-termini [27,30]. To
address, whether SKIP facilitates AR N- and C-terminal,
ligand-dependent interaction, the mammalian two-hybrid
system was used [43,44]. In the mammalian two-hybrid
system, potentially interacting protein fragments are fused
to either the GAL4 DNA binding domain (GAL4-DBD) or
the V16 transactivation domain. Interaction of the fused











Figure 1 SKIP augments AR-AF-1 dependent transactivation.
Mammalian one-hybrid analysis in HEK293 cells that were transiently
co-transfected with the GAL45E1bTATA-luciferase reporter (250 ng/well),
with AR 1–555 N-terminal domain in pM-GAL4DBD expression vector
(125 ng) or empty pM-GAL4DBD vector (125 ng), as well as with SKIP-
pCGN (100 ng) or empty pCGN (100 ng). To allow for comparison to
the N/C-interaction transfection experiments (Figure 2) the empty
vector pVP16AD containing the VP16 transactivation domain was also
transfected (125 ng). Data are relative to the control sample (no SKIP,
no AR-AF1) as means ± SEM calculated from four independent
luciferase reporter experiments, as described in Materials and Methods.
Statistically significant difference between indicated means was
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Figure 2 SKIP increases N- and C-terminal interaction of AR.
Mammalian two-hybrid analysis in HEK293 cells that were transiently
co-transfected with the GAL45E1bTATA-luciferase reporter (250 ng/
well), and as indicated, GAL4-DBD-fusion constructs and VP16-fusion
constructs of the C- or N-terminus of AR (GAL4DBD-AR 642–917
(125 ng each) and pVP16-AR1-538 (125 ng), respectively) with SKIP-
pCGN (100 ng) or empty pCGN (100 ng). Reporter activity was
determined in cells with (black bars) and without (grey bars) 1 nM
DHT stimulation overnight for 16 hours. Response of cells that did
not co-express SKIP (columns 1–4), was markedly lower than that of
cells expressing SKIP (columns 5–8). Note the discontinuous y-axis
for the relative activity. Data are relative to the control sample
(empty vectors without DHT stimulation) as means ± SEM calculated
from five independent luciferase reporter experiments, as described
in Materials and Methods. Statistically significant difference between
indicated means was determined using Student’s t-test.
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GAL4 responsive promoter. Residues 1–538 of AR were
fused to the VP16 activation domain and C-terminal AR-
LBD residues 642–917 to the GAL4 DNA binding domain
(AR642-917) to detect N/C-terminal interaction. Modula-
tion of this interaction by SKIP would alter reporter gene
expression in HEK293.
In the absence of SKIP, the AR N- and C-terminal,
ligand-dependent interaction resulted in a significant in-
crease in relative luciferase activity by 12-fold (Figure 2
column 4). SKIP also enhanced ligand-dependent ac-
tivation of the AR-LBD 642–917 construct by 9-fold
(Figure 2 column 7). Overexpression of SKIP markedly
increased ligand-dependent transcriptional activity medi-
ated by the AR N- and C-terminal constructs to ~300-
fold over control levels (Figure 2 column 8 compared
with column 4). Thus SKIP facilitates the ligand-
induced, interdomain interaction of the N- and C-termini
of AR or processes downstream of this rearrangement,
augmenting AR transcriptional activity by an order of
magnitude.
SKIP increases AR-dependent transcription in prostate
cancer cell lines
To provide further evidence that SKIP is a co-activator
of AR function, the effects of SKIP overexpression on
AR–dependent transcription were assessed using the
androgen-responsive mouse mammary tumour virus
(MMTV) MMTV-luc and the prostate-specific antigen
(PSA) PSA-luc luciferase reporter plasmids in a prostate
cancer cell line. We used the AR-negative PC3 cell line,where we overexpressed WT AR. In these cells SKIP
overexpression augmented basal ligand-independent
MMTV reporter activity ~6-fold. Additional stimulation
with the AR ligand DHT (0.01 to 10 nM) increased ac-
tivity ~18-fold over control levels (no SKIP, empty pSG5
vector only, no DHT), without any apparent dose-
dependence (Figure 3). On the other hand, SKIP alone
induced only a 2-fold increase in basal PSA-reporter ac-
tivity. This was however markedly and dose-dependently
increased by DHT (8-60- fold over control levels), as
compared to PC3-cells without co-transfected SKIP (up
to 10-fold over control levels).
These results suggest that SKIP augments DHT-induced
MMTV- and PSA-reporter activity several-fold, with a
response pattern that depends on the reporter gene
construct.
SKIP co-immunoprecipitates with androgen receptor
SKIP has been shown to interact with a number of nu-
clear hormone receptors via its helical repeat domain
[2]. We therefore investigated, whether SKIP is also in a
complex with AR in a co-immunoprecipitation experi-
ment (Figure 4).
We co-expressed AR with SKIP in COS-7 cells and
precipitated bound proteins from the cell lysates using
anti-AR or anti-HA antibodies (Figure 4). HA tagged
SKIP proteins (~62 kD) were specifically detected in
AR-immunoprecipitates in similar amounts, irrespective



























Figure 3 SKIP augments AR-dependent transcription in
prostate cancer cells. Luciferase reporter transactivation assays
were performed in PC3 prostate cancer cells using transiently
transfected MMTV- and PSA-luciferase reporters (250 ng/well) with
SKIP-pSG5 expression plasmid (200 ng) or empty vector pSG5
(200 ng) as indicated. As PC3 cells have no endogenous AR
expression, pCMV-AR WT expression plasmid (25 ng/well) was also
transfected in these cells. Data are relative to the no SKIP and no
ligand control, which was set as one and expressed as mean ± SEM
calculated from 3 independent experiments.
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the inverse experiment showed that AR protein (~110 kD)
was specifically detected in HA-SKIP immunoprecipitates
(Figure 4 lane 6 and 7).
In conclusion, these data suggest that AR and SKIP in-
teract in a specific complex.
FRET experiments reveal interaction of AR and SKIP in the
nucleus
Finally, we wanted to monitor AR and SKIP interaction
in intact living cells and provide evidence for their direct
interaction, using Förster/fluorescence resonance energy
transfer (FRET) imaging. We transiently co-expressed AR,
which was C-terminally tagged with ECFP (AR-ECFP) as
fluorescent donor, and SKIP, N-terminally tagged withHA
DHT 
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Figure 4 SKIP and androgen receptor co-immunoprecipitate. Co-immu
length AR WT plasmid and HA-SKIP-plasmid as indicated and described in
and AR-positive (N20-antibody) proteins (right) are shown. rIgG stands for r
out in presence or absence of 1 nM DHT, as indicated. Lanes 5 and 10 sho
Approximate molecular weights are as indicated on the left. Arrow shows
positive controls. Blots are representative of three independent repeats.EYFP (EYFP-SKIP) as an acceptor in BHK cells (Figure 5).
The EYFP-SKIP construct localized to small nuclear struc-
tures of various sizes (Figure 5A; Additional file 1). For
our FRET experiments, we selected for those cells that
contained larger SKIP-positive nuclear structures. Note,
that even under serum starvation, cells exhibited various
degrees of nuclear co-localization of AR-ECFP and EYFP-
SKIP (data not shown). Using donor-dequenching FRET
experiments on maximally DHT stimulated BHK cells, we
measured a high FRET efficiency of 57±3%, as compared
to 11±2% background (Figure 5B).
In order to gain further insight into the temporal cha-
racteristics of this interaction, we followed the DHT in-
duced nuclear translocation of AR-ECFP to EYFP-SKIP
positive structures in live BHK cells. We used sensitised
acceptor emission FRET imaging with fully crosstalk
corrected FRET images [45]. When stimulated with DHT
(Figure 5C), AR-ECFP accumulated on EYFP-SKIP posi-
tive structures of the nucleus within 3 minutes (Figure 5D),
with concomitant increase in the FRET signal (Figure 5E;
Additional file 2). On individual SKIP-positive nuclear
structures, the FRET signal first increased at the periphery
and then progressed towards the centre. Thereafter, the
FRET signal decreased, due to a drop in the EYFP-SKIP
signal, which was not due to photobleaching caused by
progressive scanning of the sample (data not shown).
In conclusion, FRET-experiments provide additional
evidence that a direct and transient interaction of AR
and SKIP occurs within the nucleus, which increases
within minutes after DHT-stimulated nuclear transloca-
tion of AR.
Discussion
In this study we provide evidence that SKIP acts as a co-
regulator of AR transcription. Using mammalian one- andAR 
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noprecipitation experiments in COS-7 cells co-transfected with full-
Materials and Methods. AR-bound and HA-positive (left) or SKIP-bound
abbit IgG and represents a negative control. Experiments were carried
w blotted lysates as input controls for the immunoprecipitation.













































Figure 5 AR interacts with SKIP after nuclear translocation on SKIP-positive nuclear speckles. (A,B) Donor dequenching and (C-E)
sensitised acceptor emission FRET imaging data of AR-ECFP and EYFP-SKIP co-expressed in BHK cells. (A) BHK cells were transiently transfected
with AR-ECFP and EYFP-SKIP. Before being fixed with 4% PFA, cells were stimulated for 2.5 min with 10 nM DHT at room temperature. The
acceptor was then bleached and the increase of the donor-fluorescence was monitored in the donor channel, using confocal imaging. (B) The
average FRET efficiency of AR-ECFP/EYFP-SKIP (8 images, 24 speckles), E%=57±3% (mean±SEM) was significantly higher (P<0.001, 2-tailed
Student’s t-test), than that of the control FRET-pair, ECFP/EYFP-SKIP, E%=11±2% (mean±SEM) (3 images, 9 speckles) on EYFP-SKIP positive nuclear
speckles. This is in line with a strong interaction between AR and SKIP on these structures. (C) Representative time series of serum starved BHK
cells, transiently transfected with AR-ECFP and EYFP-SKIP that were stimulated with 10 nM DHT (+DHT). Using confocal imaging, nuclear
translocation of AR-ECFP and FRET-changes (FRET2) were measured over time. Time points are shown in FRET2 images. The approximate
boundary of the nucleus is indicated in the first AR-ECFP image. (D) The nuclear translocation index of data in C was calculated using the largest
speckle (arrow in first image) and a region in the cytoplasm (asterisk) (apparent translocation half-time, τ0.5=213±9 s). (E) The change of the FRET2
signal (FRET2) and the FRET2 signal normalized with the unprocessed acceptor signal (FRET2/Ac) were averaged over the whole nucleus for each
time point. Both FRET signals reached their maximum at ~ 129 s after DHT addition, corresponding to ~ 32% translocation. Subsequently the
FRET signal decreased, as the fluorescence of EYFP-SKIP disappeared.
Abankwa et al. BMC Biochemistry 2013, 14:10 Page 5 of 9
http://www.biomedcentral.com/1471-2091/14/10two-hybrid-experiments, we showed that SKIP augments
AR AF-1 ligand-independent transcriptional activity and
AR ligand-dependent AF-1 and AF-2 (AR N/ C-terminal)
transcriptional interaction. Moreover, SKIP augmented
AR-dependent transcription with two ARE-containing re-
porters in prostate cancer PC3 cells. Immunoprecipitation
and FRET-experiments showed that AR interacts with
SKIP and that the AR translocates to the nucleus within
minutes after ligand stimulation to interact with SKIP.
FRET detects proximities of 3–7 nm for ECFP/EYFP-
FRET pairs [46], which is a distance that can in most cases
be regarded to report on direct interactions, consideringthat the size of the fluorescent proteins is already 2 nm ×
4 nm [47]. The observed high FRET efficiency between
AR-ECFP/ EYFP-SKIP on the speckle patterned SKIP-
positive structures is therefore in agreement with a direct
interaction of these proteins.
Our FRET data are supported by our one- and two-
hybrid data, which suggest that SKIP can activate both the
N- and C-terminus of AR. Therefore, FRET-fluorophores
on the C-terminus of AR and N-terminus of SKIP may
come into very close proximity, despite the relatively
large size of both proteins. The strong increase of FRET
upon DHT-stimulated nuclear translocation of AR-
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nuclear speckles, can be explained by the fact that an
excess of the acceptor, EYFP-SKIP, leads to high FRET-
levels in a molecular complex, where the donor-
acceptor-ratio is 1: >1 [48].
Nuclear speckles form a functional compartment
within the nucleus that include splicing factors. Active
gene transcription coupled with pre-mRNA splicing is
thought to occur at the periphery of the splicing factor
compartment [49-51]. It was therefore intriguing to see
that the FRET between SKIP and AR increased from the
outside to the inside of the speckle-like SKIP-positive
structures. However, as fluorescently tagged proteins had
to be overexpressed, care must be taken when relating
the magnitude of the FRET with the affinity of the two
proteins under physiological conditions. On the other
hand, overexpression does not seem to induce random
interaction in our experiments, as the interaction only
significantly increased a) after DHT-stimulation and b)
involving a translocation from the cytoplasm to the nu-
cleus. We cannot say, whether AR is in addition targeted
to other nuclear compartments.
It is of interest that the AR AF-1 domain has been
shown to interact within nuclear speckles with another
splicing factor ANT-1 (homologous to yeast splicing fac-
tor Prp6p) [52]. This distribution resembles the AR-SKIP
co-localization that we have observed (Figure 5). Thus AR
interaction with SKIP and SKIP enhancement of AR AF-1
transcriptional activity is similar to AR/ ANT-1-dependent
augmentation of transcription and splicing. Therefore, fur-
ther studies will be required to determine if SKIP, like
ANT-1 may recruit AR into a transcription-splicing cou-
pled machinery.
Interestingly, the SKIP-EYFP signal disappeared com-
pletely ~16 minutes after DHT mediated translocation
of AR to the nucleus, suggesting AR-mediated degra-
dation or masking of SKIP. Loss of the SKIP-EYFP signal
started soon after the maximum FRET was reached, rai-
sing the possibility that a regulated degradation is trig-
gered at high AR concentrations. The AR has been
previously linked to proteasome-mediated degradation,
by its interaction with ubiquitin protease USP10 [53],
the ubiquitin ligase ARNIP [54] and sensitivity of AR
transactivation to proteasome inhibitors [55].
AR transcriptional activity is dependent on its N-terminal
and C-terminal domains, which if artificially isolated can
act in a ligand-independent (AF-1) and ligand-dependent
(AF-2) manner, respectively [23,34]. Immunoprecipitation
and FRET-data allow us to explain the transactivation data
by the direct interaction of SKIP with AR, however details
of the exact mechanism are still unclear. We showed that
the AR N-terminal domain was sufficient to engage SKIP
to increase transactivation. It is possible that in a transc-
riptionally active complex, such as that induced by theN-terminal AR fragment, SKIP is engaged in the recruit-
ment of general co-regulators such as N-CoR and p300 [7].
In line with the latter interpretation, it was previously found
that AR ligand-dependently interacts with the nuclear re-
ceptor co-repressor, N-CoR [56], which also interacts with
SKIP [7].
Moreover, our two-hybrid data indicate that SKIP bi-
functionally interacts with the N- and C-termini of AR, or
at least facilitates this N/C- interaction. Interestingly,
Saitoh et al. [37] observed something similar for the effect
of the co-regulator CBP, which is also required for nuclear
foci or speckle formation. In addition, SRC1 also modu-
lates N/C-terminal interactions [57], however, this and its
co-regulator activities are handled by distinct parts of the
protein with an apparently higher significance for its
LXXLL-motif independent interaction [58]. Moreover, co-
regulators were shown to modulate the N/C-interaction,
in a cell type dependent manner. Correspondingly, their
effect on the N/C-interaction did not always correlate with
their effects on AR-mediated transactivation or cell
growth, which may highlight the importance of specific
microenvironments that influence this interaction [57].
This may be explained by the assumption that the AF-1
may be the major transactivator under normal physio-
logical conditions, while type I co-regulators come into
play, if their concentration is high, such as observed in re-
current prostate cancer [28].
Conclusions
In conclusion, our data suggest SKIP as a novel AR co-
activator that enhances its AF-1 function and interdomain-
interaction, as well as AR-dependent transcription. The
diverse network of interactions shown for SKIP, in particu-
lar with nuclear hormone receptors, explains its impact on
several signalling pathways involved in growth and develop-




HEK293 cells (origin: H. sapiens: embryonal kidney
cells); PC3 (origin: H. sapiens: prostate cancer cells) were
maintained in medium with 10% foetal calf serum and
plated 24–36 hours before transfection into 24 well
plates at a density of 2×104 cells (HEK293) or 2.5×104
cells (PC3) per well so that at time of transfection cells
were about 75% confluent. Cells were transfected over-
night with Fugene 6 (Roche) following the manufac-
turer’s instructions, using 1.5 μl Fugene per 0.6 μg of
total plasmid DNA per well. The ligand DHT in
DMEM/F12 for HEK293 cells of RPMI for PC3 cells was
added to medium supplemented with 2% charcoal
stripped FCS for 24 hours. Medium was removed and
cells were washed once with ice cold PBS and then lysed
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performed in triplicate with the Firefly luciferase assay
kit (Promega) and measured on a luminometer (Berthold
LB953 Autolumat), as described previously [7]. The PC3
cell line expresses no endogenous AR [59].
Co-immunoprecipitation and western blotting
Co-immunoprecipitations were performed as follows.
COS-7 cells (origin: Cercopithecus aethiops, African green
monkey, derived from CV-1 cells by SV40 mediated
immortalization [60]) cultured under standard conditions
in 10 cm culture dish (NUNC) were co-transfected using
Lipofectamine™ 2000 (Invitrogen) with pCMV-AR and/or
SKIP-pCGN plasmid DNA (10 μg each) and cultured in
the presence or absence of 1 nM DHT. Cells were har-
vested 48 h after transfection and were lysed in 0.5 ml of
cold RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
1 mM EDTA, 0.1% SDS, 0.5% deoxcholic acid, 1% Tri-
ton X-100) containing 1 mM PMSF and proteinase in-
hibitors (Roche). Lysates were sonicated for 30 seconds
on ice and centrifuged to remove cell debris then pre-
clarified by incubation with 40 μl of 50% protein G-
Sepharose beads (Amersham) and 1 μg of rabbit IgG
(Dako) at 4°C for 1 hour with slow rotation to reduce
non-specific binding. After pelleting the beads, the ly-
sates were incubated with rabbit anti-AR antibody, N20
(Santa Cruz Biotechnology), and rabbit anti-HA anti-
body (Santa Cruz Biotechnology), respectively, at 4°C
overnight, and followed by incubating with 20 μl of
50% protein G-Sepharose beads at 4°C for 1 hour to re-
cover AR or HA-SKIP containing protein complexes.
The immunoprecipitates were washed 5 times with
cold RIPA buffer and resuspended in 20 μl of sample
buffer before subjecting to western blotting with anti-
bodies to AR or HA-SKIP. Briefly, parts of the
immunoprecipitated sample was resolved on an 8%
SDS-PAGE, blotted and probed for HA-tagged SKIP
using anti-HA antibody. The other parts were sepa-
rated on gels, blotted and probed with anti-AR anti-
body, N20 to detect an AR N-terminal fragment. The
probed blots were incubated with anti-rabbit IgG HRP
(Amersham) and imaged using ECL (Amersham).Plasmid constructs
SKIP-pSG5, SKIP-pM, SKIP-pCGN were previously de-
scribed [7,8]. All mammalian one and two-hybrid plasmids
(pM-GAL4DBD and pVP16AD; Clontech State, USA) and
the GAL45E1bTATA-luciferase reporter [61] were previously
described [7]. The MMTV-luciferase reporter MMTV-luc
was provided by Dr. R.M. Evans, Salk Institute, La Jolla,
CA and the PSA-luciferase reporter plasmid (pGL3-
PSA540-enhancer, PSA-luc) provided by Bristol-MyersSquibb (Princeton, NJ) as previously described [62]. The
vector pM-GAL4DBD-AR-AF1 expressed the activation
function 1 fragment of AR (residues 1–555). The vectors
pM-GAL4DBD-AR642-917 and pVP16-AR1-538 were as
described [41]. pCMV-AR WT-pCMV3.1 plasmid for
co-immunoprecipitation experiment was previously de-
scribed [63,64]. All AR constructs are derived from human
AR. EYFP-SKIP human Skip cDNA was amplified by PCR
using primer pairs (50-TTT GAA TTC ATG GCG CTC
ACC AGC TTT TTA CCT GC-30 and 50-TTT GTC GAC
TAT TCC TTC CTC CTC TTC TTG CC-30), phosphory-
lated by T4 polynucleotide kinase, and cloned into the SmaI
site of pEYFP-C1 (Clontech). The AR-pECFP-N1 plasmid
was as previously described [37].Donor dequenching and sensitised acceptor FRET
imaging experiments
FRET experiments were performed in BHK-21 cells (ori-
gin: Mesocricetus auratus, golden hamster) that were cul-
tured and transfected as previously described. BHK cells
were chosen as they were easy to transfect and showed
good expression of the constructs. Donor dequenching ex-
periments were carried out, using a LSM 510 Meta con-
focal microscope (Zeiss). Fluorescent 12 bit images were
recorded in the donor- (ex 405 nm, em 530–600 nm) and
acceptor- (ex 514 nm, em 530–600 nm) channels before
and after bleaching of EYFP (at 514 nm with 100% laser
transmission at 50% output in a ROI circumscribing nu-
clear speckles using 200 iterations). Average bleaching of
the EYFP-signal was 98.3±0.5% (sem). The average appa-
rent donor dequenching FRET-efficiency was calculated
on individual EYFP-SKIP positive speckles, as: E=1-
Dbefore/Dafter, where Dbefore/after are the background
corrected average donor channel signals before and after
bleaching, respectively. On each recorded image 3 differ-
ent SKIP-positive speckles were analysed. Sensitized ac-
ceptor emission FRET imaging was carried out essentially
as described [45]. However, due to the inherently large dif-
ference in donor and acceptor expression, only the FRET
index image, FRET2 [65], was calculated for each time
point. The colour-lookup-table was assigned to the
FRET2-images using Image J. The video showing the
donor, FRET and acceptor-images was generated using
Image J and Quick Time Pro. The translocation index, TL,
was calculated on the indicated regions using the intensity
of the AR-ECFP on the speckle, S, and the AR-ECFP in-
tensity of a reference region in the cytoplasm, C: TL=S/C.
For graphical representation and curve fitting, this value
was then normalized using the TL at time 0 and at the last
time point 988 s: TLnorm=(TL-TL0)/(TL988-TL0). To deter-
mine the translocation half-time, τ0.5, where 50% trans-
location occurred, a monoexponential function was fitted:
TLnorm=1-exp(−t/τ), with τ0.5= − τ ln0.5.
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Additional file 1: Confocal imaging data of EYFP-SKIP showing its
diverse speckled distribution patterns in BHK cells.
Additional file 2: The video shows the donor- (left, green),
calculated FRET- (middle, colour coded), and the acceptor-images
(right, yellow). DHT was added in frame 1 (time given in middle panel)
at 10 nM. The donor images show a DHT induced increase in AR-ECFP
translocation from the cytoplasm to the EYFP-SKIP positive nuclear
speckles. This leads to a transient increase in FRET on the speckles,
suggesting an increased number of AR/SKIP interactions. The FRET signal
subsequently decreased, as the signal of EYFP-SKIP diminished.
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